1Division of Vascular Surgery.
2Department of Surgery.
J Neurosurg. 2018 Dec 1;129(6):1522-1529. doi: 10.3171/2017.8.JNS171142. Epub 2018 Jan 26.
OBJECTIVEIntracranial hemorrhage (ICH) associated with cerebral hyperperfusion syndrome is a rare but major complication of carotid artery revascularization. The objective of this study was to compare the rate of ICH after carotid artery stenting (CAS) with that after endarterectomy (CEA).METHODSThe authors performed a retrospective population-based cohort study of patients who underwent carotid artery revascularization in the province of Ontario, Canada, between 2002 and 2015. The primary outcome was the rate of ICH that occurred within 90 days after carotid artery intervention among patients who underwent CAS versus that of those who underwent CEA. The authors used inverse probability of treatment weighting and propensity scores to account for selection bias. In sensitivity analyses, patients who had postprocedure ischemic stroke were excluded, and the following subgroups were examined: patients with symptomatic and asymptomatic carotid artery stenosis, patients treated between 2010 and 2015, and patients aged ≥ 66 years (to account for antiplatelet and anticoagulant use).RESULTSA total of 16,688 patients underwent carotid artery revascularization (14% CAS, 86% CEA). Patients with more comorbid illnesses, symptomatic carotid artery stenosis, or cardiac disease and those who were taking antiplatelet agents or warfarin before surgery were more likely to undergo CAS. Among the overall cohort, 80 (0.48%) patients developed ICH within 90 days (0.85% after CAS, 0.42% after CEA). The 180-day mortality rate after ICH in the overall cohort was 2.7%, whereas the 180-day mortality rate among patients who suffered ICH was 42.5% (40% for CAS-treated patients, 43.3% for CEA-treated patients). In the adjusted analysis, patients who underwent CAS were significantly more likely to have ICH than those who underwent CEA (adjusted OR 1.77; 95% CI 1.32-2.36; p < 0.001). These results were consistent after excluding patients who developed postprocedure ischemic stroke (adjusted OR 1.90; 95% CI 1.41-2.56) and consistent among symptomatic (adjusted OR 1.74; 95% CI 1.16-2.63) and asymptomatic (adjusted OR 1.75; 95% CI 1.16-2.63) patients with carotid artery stenosis, among patients treated between 2010 and 2015 (adjusted OR 2.21; 95% CI 1.45-3.38), and among the subgroup of patients aged ≥ 66 years (adjusted OR 1.53; 95% CI 1.05-2.24) after adjusting for medication use.CONCLUSIONSCAS is associated with a rare but higher risk of ICH relative to CEA. Future research is needed to devise strategies that minimize the risk of this serious complication after carotid artery revascularization.
颅内出血(ICH)与脑高灌注综合征有关,是颈动脉血运重建的罕见但严重的并发症。本研究旨在比较颈动脉支架置入术(CAS)与颈动脉内膜切除术(CEA)后 ICH 的发生率。
作者对加拿大安大略省 2002 年至 2015 年间接受颈动脉血运重建的患者进行了回顾性基于人群的队列研究。主要结局是 CAS 与 CEA 患者在颈动脉介入治疗后 90 天内发生 ICH 的发生率。作者使用逆概率治疗加权和倾向评分来纠正选择偏倚。在敏感性分析中,排除了术后发生缺血性卒中的患者,并对以下亚组进行了研究:有症状和无症状颈动脉狭窄的患者、2010 年至 2015 年期间接受治疗的患者以及年龄≥66 岁的患者(以考虑抗血小板和抗凝药物的使用)。
共 16688 例患者接受了颈动脉血运重建(14%CAS,86%CEA)。合并症较多、有症状颈动脉狭窄或心脏病以及术前正在服用抗血小板药物或华法林的患者更可能接受 CAS。在总体队列中,80 例(0.48%)患者在 90 天内发生 ICH(0.85%在 CAS 后,0.42%在 CEA 后)。总体队列中 ICH 后 180 天死亡率为 2.7%,而发生 ICH 患者的 180 天死亡率为 42.5%(40%为 CAS 治疗患者,43.3%为 CEA 治疗患者)。在调整分析中,与 CEA 相比,接受 CAS 的患者发生 ICH 的可能性显著更高(调整后的 OR 1.77;95%CI 1.32-2.36;p<0.001)。排除术后发生缺血性卒中的患者后(调整后的 OR 1.90;95%CI 1.41-2.56)和排除有症状(调整后的 OR 1.74;95%CI 1.16-2.63)和无症状(调整后的 OR 1.75;95%CI 1.16-2.63)颈动脉狭窄患者以及在 2010 年至 2015 年期间接受治疗的患者(调整后的 OR 2.21;95%CI 1.45-3.38)以及年龄≥66 岁的亚组患者(调整后的 OR 1.53;95%CI 1.05-2.24)后,结果仍一致,并调整了药物使用情况。
与 CEA 相比,CAS 与罕见但更高的 ICH 风险相关。需要进一步研究制定策略,以最大程度地降低颈动脉血运重建后发生这种严重并发症的风险。